CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

• CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.
  
  
• CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735.
  
  
• CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation.

BASEL, Switzerland, March 11, 2025 -- CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the signing of a strategic partnership with Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage company focused on developing novel therapies for metabolic and endocrine disorders. Under this multi-year supply contract, CordenPharma provides development and manufacturing services for clinical and commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735, a Dual GLP-1/GIP Receptor Agonist, across the full supply chain from drug substance to drug product for both its subcutaneous and oral peptide formulations.